

Session Title: #103: Therapeutic Options for Patients with Breast Cancer with a Family History or BRCA Mutation

Session Type: Education Session

Date: Saturday, June 5

Location: E Arie Crown Theater

Time: 8:00 AM - 9:15 AM

- Surgical options for breast cancer patients with a BRCA 1/2 mutation or a familial predisposition

Marian B.E. Menke-Pluymers, MD, PhD

- Radiation therapy and hereditary breast cancer

Abram Recht, MD

- Systemic therapy in BRCA1 and BRCA2 mutation carriers with breast cancer

Susan M. Domchek, MD

Session Title: #268: Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Session Type: Special Session

Date: Saturday, June 5

Location: N Hall B1

Time: 9:30 AM - 12:00 PM

- Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Daniel D. Von Hoff, MD

Session Title: #51: Future Directions in the Management of Endometrial Cancer

Session Type: Education Session

Date: Saturday, June 5

Location: E Arie Crown Theater

Time: 1:15 PM - 2:30 PM

- Surgically Staging of Endometrial Cancer: The Controversy Continues

David E. Cohn, MD

- Optimizing Adjuvant Therapy in the Treatment of Early Stage Endometrial Cancer Patients

Carlen Creutzberg, MD, PhD

- Incorporating Novel Biologic Therapies into Endometrial Cancer Treatment

Gini F. Fleming, MD

Session Title: #202: Gynecologic Cancer

Session Type: General Poster Session

Date: Saturday, June 5

Location: S Hall A2

Time: 2:00 PM - 6:00 PM

45A #5034-Use of 99mTc-EC20 (a folate-targeted imaging agent) to predict response to therapy with EC145 (folate-targeted therapy) in advanced ovarian cancer.

James Thomas Symanowski

45B #5035-Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor positive platinum resistant ovarian cancer.

Guenter Emons, MD, PhD

45C #5036-Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response (CR) post-first-line chemotherapy (FLCT): Preliminary results of the randomized, double-blind, placebo-controlled, multicenter MIMOSA trial.

Paul Sabbatini

45D #5037-Tolerability and pharmacokinetics of intraperitoneal carboplatin and paclitaxel with intravenous bevacizumab.

Carolyn N. Krasner

45E #5038-A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the Princess Margaret Hospital, The University of Chicago, and California cancer Phase II Consortia.

Raimundo Correa

45F #5039-Intraoperative immunotherapy with the trifunctional antibody catumaxomab in patients with ovarian cancer: Results from a phase II study.

Radoslav Chekerov

45G #5040-The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis of ovarian origin.

Michele De Tursi

45H #5041-Preliminary experience with the use of chemotherapy (CT) following treatment with olaparib, a poly ADP-ribose polymerase inhibitor (PARPi), in patients with *BRCA1/2*-deficient ovarian cancer (BDOC).

Joo Ern Ang

46A #5042-Exposure-response relationships of AMG 386 in combination with weekly paclitaxel in advanced ovarian cancer: Population pharmacokinetic/pharmacodynamic (PK/PD) modeling to facilitate phase III dose selection.

Jianfeng Lu

46B #5043-Pegylated liposomal doxorubicin (PLD) treatment for recurrent epithelial ovarian cancer (rEOC): Implications of BRCA mutations.

Tamar Safra

46C #5044-Health-related quality of life (HRQL) and progression-free survival (PFS) in patients with recurrent ovarian cancer: Results from the CALYPSO trial.

Michael Brundage

46D #5045-Safety and tolerability of a novel IL-12 gene therapeutic administered in combination with carboplatin/docetaxel in patients with recurrent ovarian cancer.

Kursheed Anwar

46E #5046-Activity of docetaxel plus trabectedin in recurrent or persistent ovarian and primary peritoneal cancer: A phase II study of the Gynecologic Oncology Group (GOG).

Bradley J. Monk

46F #5047-Phase III randomized trial of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) versus RH for bulky stage I/II cervical cancer: Update of Japan Clinical Oncology Group (JCOG) protocol 0102.

Noriyuki Katsumata

46G #5048-Prognostic role of lymph node status in primary advanced ovarian cancer after complete resection or residual disease less than 1 cm: Results of a meta-analysis of the AGO-OVAR meta-database.

Philipp Harter

46H #5049-Phase Ib study of AMG 386 combined with either pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with advanced ovarian cancer.

Robert M. Wenham

47A #5050-Phase Ib study of RAD001 (R) with pegylated-liposomal doxorubicin (PLD) in patients with advanced solid tumors.

Antonella Perotti

47B #5051-Intraperitoneal mitoxantrone in the treatment of recurrent ascites from progressive epithelial ovarian cancer.

Marco Marinaccio

47C #5052-The impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: A retrospective Japan clear cell carcinoma study.

Masashi Takano

47D #5053-How does 18f-FDG PET-CT scan affect clinical judgment and change treatment decisions in patients with epithelial ovarian cancer?

Fatih Selcukbiricik

47E #5054-Laparoscopic hysterectomy versus abdominal hysterectomy in early-stage endometrial cancer.

Marian JE Mourits

47F #5055-ERCC1 status in patients with locally advanced cervical cancer treated with RT or CRT: A multicenter clinicopathologic analysis.

Corinne M Doll

47G #5056-The combination of [18f]fluorodeoxy-glucose and 16alpha-[18f]fluoro-17beta-estradiol positron emission tomography for identifying leiomyosarcoma in uterine smooth muscle tumors.

Yoshio Yoshida

47H #5057-Low-grade serous primary peritoneal carcinoma.

David Marc Gershenson

48A #5058-Significance of the hedgehog (Hh) pathway in ovarian cancer xenograft growth.

Bo R Rueda

48B #5059-A phase I dose escalation study of AGS-8M4 (ASP6183), an anti-AGS-8 fully human antibody, in advanced ovarian cancer.

Deborah Kay Armstrong

48C #5060-Trabectedin (Tr) as single agent in relapsed ovarian cancer (ROC) patients (pts) with a platinum-free interval (PFI) of 6 to 12 months.

JM del Campo

48D #5061-A novel proteomics biomarker panel as a diagnostic tool for patients with ovarian cancer.

Claus Kim Hogdall

48E #5062-New aspects in the treatment of cervical cancer complicated by pregnancy: Laparoscopic nodal evaluation before oncologic treatment delay.

Giovanni Favero

48F #5063-Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: Single or combination chemotherapy?

Gerard Adams

48G #5064-Pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) given alone and with bevacizumab (B) in patients with recurrent epithelial ovarian cancer (rEOC).

Franco Muggia

48H #5065-Preclinical evaluation of PARP inhibition as a treatment for endometrioid endometrial carcinomas.

Konstantin J Dedes

49A #5066-Development of a gene expression-based test for the detection of endometrial cancer in uterine aspirates.

Elisabet Rosell

49B #5067-Concurrent weekly cisplatin versus gemcitabine with radiation in advanced carcinoma cervix: A study on 120 patients.

Dipti Rani Samanta

49D #5069-Prognostic role of dendritic cells and T lymphocytes in the clinical outcomes of stage III ovarian cancer.

Wei Ding

49E #5070-The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma.

Naveen Vasudev

49F #5071-Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): A planned 200-pt interim safety analysis of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG Intergroup Study (HECTOR).

Werner Meier

49G #5072-Assessment of endometrial sampling as a predictor of final surgical pathology in endometrial cancer.

Limor Helpman

49H #5073-Characteristics and outcomes of pharmaceutical versus nonpharmaceutical affiliated phase III clinical trials on targeted agents for cancer therapy.

Katherine Fuh

50A #5074-Activity of dual PI3K/mTOR inhibitor, NVP-BEZ235, and mTOR inhibitor, RAD001 (everolimus), in endometrial cancer cell lines.

Keiko Shoji, MD

50B #5075-The association between quality of life and overall survival in ovarian cancer patients during adjuvant chemotherapy: A Gynecologic Oncology Group study.

Vivian E. Von Gruenigen

50C #5076-Immunohistochemical expression of ER and PR and outcomes in patients with newly diagnosed uterine leiomyosarcoma.

Mario M. Leitao

50D #5077-CA125 response to bevacizumab in recurrent ovarian cancer.

Roisin Eilish O'Cearbhaill

50E #5078-Angiogenesis-related gene profile to predict outcome to multimodal therapy in advanced ovarian carcinoma.

Jorge Barriuso

50F #5079-Expression of tumor-associated antigen c-terminal binding protein-2 in epithelial ovarian tumors and effect on response to HDAC inhibitors in vitro.

Lisa M Barroilhet

50G #5080-The value of early decrease in CA125 levels as a prognostic or surrogate marker for disease progression in patients with recurrent ovarian cancer: Results from the CALYPSO study.

Robert John Simes

50H #5081-Clinical trials of WT1 peptide vaccine to gynecologic malignancies that are resistant to conventional therapies.

Takashi Miyatake, Dr

51A #5082-Time to platinum resistance (TTPR) as a novel surrogate end-point for trials in ovarian cancer.

Ilya Pokataev

51B #5083-Sequential angiogenic blockade for the treatment of recurrent ovarian cancer.

Ursula Matulonis

51C #5084-Interval from neoadjuvant chemotherapy to interval debulking surgery in advanced ovarian cancer: Is this a prognostic indicator?

Roopa Hariprasad

51D #5085-Associations between age and quality of life in advanced ovarian cancer.

Alexi A. Wright

51E #5086-Effects of treatment by temsirolimus on patients with clear cell carcinoma of the ovary.

Yoshihiro Kikuchi

51F #5087-Regulation of proliferation in endometrial carcinoma cell line by the epidermal growth factor receptor and estrogen receptor beta.

John H. Farley, MD

51G #5088-Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients' survival.

Julia Dorn, Dr

51H #5089-Interleukin-6 as a therapeutic target in advanced ovarian cancer.

Jermaine IG Coward

52A #5090-Relative conditional survival in 41,476 patients with ovarian cancer.

Rachel Ware

52B #5091-Fertility-sparing management with progestin for young women with early-stage endometrial cancer and complex hyperplasia with atypia.

Jeong-Yeol Park

52C #5092-Oxaliplatin plus continuous infusion topotecan: An ongoing phase II study for recurrent ovarian cancer-A New York Cancer Consortium study (#N01-CM62204).

Stacey Stein

52D #5093-Combination therapy with paclitaxel, carboplatin, and megestrol acetate for advanced-stage and recurrent endometrial carcinoma: A phase II study.

Kerri S Bevis

52E #5094-Rapid, durable restoration of malignant ascites-derived antigen presenting cell immunogenicity by toll-like receptor agonists.

Stephanie Jean

52F #5095-Vaginal cuff brachytherapy combined with carboplatin and paclitaxel as adjuvant therapy for high-intermediate-risk patients with endometrial carcinoma.

Lisa M Landrum

52G #5096-Prognosis and prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma).

Catherine Uzan

52H #5097-Sexual activity and functioning in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer.

Trond Melbye Michelsen

53A #5098-The efficacy and toxicity of belotecan (CKD-602) combined with platinum in patients with recurrent epithelial ovarian cancer.

Yong-Man Kim

53B #5099-Proliferation and lymphangiogenesis markers, and risk of lymph-nodal metastasis in early cervical cancer.

Stefano Bogliolo

53F #5100-Prognostic impact of primary surgical outcome on survival after recurrence in patients with advanced ovarian cancer: Analysis of prospective randomized phase III trials.

Sven Mahner

53G #5101-Relationship between ERCC1 C8092A and Mad1 G558A polymorphism with disease progression, and survival in patients with advanced epithelial ovarian cancer treated with induction chemotherapy with carboplatine paclitaxel (PC).

LA Herrera Montalvo

54A #5103-Inactivation of O6-methylguanine-DNA methyltransferase (MGMT) by promoter hypermethylation: A key factor of epithelial ovarian carcinogenesis in specific histologic types.

Hyun-Jin Roh

54B #5104-Neoadjuvant chemotherapy in second trimester pregnant patients with cervical cancer: First study on in vivo concentrations of cisplatin in fetal and maternal compartments.

Simone Marnitz

54F #5105-Development of a nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer based on the CALYPSO trial.

Chee Khoon Lee

54G #5106-What do primary and recurrent ovarian cancer patients (OC) expect from their doctors? Final results of a German survey in 608 patients.

Gülten Oskay-Özcelik

54H #5107-A phase I study of the infectivity enhanced CRAAd Ad5- Δ 24RGD for recurrent gynecologic cancer.

David T Curiel

55A #5108-A phase I/II study of topotecan and sorafenib in recurrent, platinum-resistant ovarian cancer: HOG GYN-111.

Daniela Matei

55B #5109-Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for advanced ovarian cancer.

Edward J. Tanner

55C #5110-Prognostic relevance of resection margin distance for loco-regional control in vulvar cancer.

Linn Woelber

55D #5111-Predictive value of circulating tumor cells for response to therapy in women with recurrent epithelial ovarian cancer.

David Kindelberger

55E #5112-Can we increase response rate (RR) and overall survival (OS) by individualizing chemotherapy in ovarian cancer (OC): The role of a new chemotherapy (CT) induced apoptosis assay.

Emery Manuel Salom

55F #5113-Ten-year relative survival for ovarian cancer.

Lauren Baldwin

55G #5114-Intraperitoneal chemotherapy: Who, what, when, and how in diverse academic settings.

Leslie R. Boyd

55H #5115-A cross sectional study on intestinal and bladder symptoms in gynecologic malignancies.

K. Pushpalatha

56A #5116-Efficacy of lower dose of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer resistant to platinum-based therapy.

Vasiliki Michalaki

56B #5117-Chemoradiation followed by adjuvant hysterectomy for the treatment of stage IB-2 cervical cancer: 10-year experience.

Glenn E. Bigsby

56C #5118-The impact of age on first-line chemotherapy treatment of epithelial ovarian cancer and primary peritoneal carcinoma.

Emmanuel Larbi

56D #5119-Clinical significance of selected angiogenesis and lymphangiogenesis modulators and markers in ovarian cancer patients.

Dagmara Klasa-Mazurkiewicz

56E #5120-Excision repair cross-complementation group 1 (ERCC1) expression as a predictor for response of neoadjuvant chemotherapy for locally advanced uterine cervix cancer.

Sang Hoon Jeon

56F #5121-Tolerability of long-term use of trabectedin (Tr) in combination with pegylated liposomal doxorubicin (PLD) in patients (pts) with relapsed ovarian cancer (ROC).

Ignacio Romero

56G #5122-The correlation of cone biopsy with findings at radical hysterectomy and the need for adjuvant radiation therapy.

Todd Patrtick Boren

56H #5123-Cisplatin (C) and ifosfamide (I) chemotherapy with vaginal cuff brachytherapy (VCBT) for treatment of uterine carcinosarcoma.

Hao Wang, MD, PhD

Session Title: #127: Complex and Recurrent Gynecologic Cancers: What's an Oncologist to Do?

Session Type: Clinical Problems in Oncology Session

Date: Saturday, June 5

Location: E451a

Time: 4:45 PM - 6:00 PM

- Recurrent Germ Cell Tumor of the Ovary

Seiko Diane Yamada, MD

- Management of recurrent leiomyosarcoma of the uterus

Martee Leigh Hensley, MD, MSc

- Management of recurrent low grade serous ovarian carcinoma

John H. Farley, MD

Session Title: #167: Highlights of the Day I including Clinical Trials Participation Awards

Session Type: Highlights of the Day

Date: Sunday, June 6

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day I including Clinical Trials Participation Awards

Everett E. Vokes, MD

- Clinical Trials Participation Awards

Douglas W. Blayney, MD

- Discussion: Lymphoma and Plasma Cell Disorders

Bruce D. Cheson, MD

- Discussion: Lung Cancer - Local/Regional and Adjuvant Therapy
Alan B Sandler, MD
 - Discussion: Patient and Survivor Care
Gretchen Genevieve Kimmick, MD
 - Discussion: Melanoma/Skin Cancers
F. Stephen Hodj, MD
-

Session Title: #56: HPV Status and Clinical Decision-making for Patients with Oropharynx Cancer

Session Type: Education Session

Date: Sunday, June 6

Location: E Hall D2

Time: 8:00 AM - 9:15 AM

- Clinical Implications of Human Papillomavirus-etiology of Head and Neck Cancers: An Update
Maura L. Gillison, MD, PhD
 - The Development of Prospective HPV-specific Head and Neck Cancer Clinical Trials
Andy Trotti, MD
 - Biological Correlates of HPV Tumor Status
Lisa F. Licitra, MD
-

Session Title: #154: Gynecologic Cancer

Session Type: Oral Abstract Session

Date: Sunday, June 6

Location: E Arie Crown Theater

Time: 9:30 AM - 12:30 PM

- Gynecologic Cancer
Amit M. Oza, BSc, MBBS, MD, FRCPC, FRCP
- Gynecologic Cancer
Ernst Lengyel, MD, PhD
- #5003-A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA).
Karen H. Lu

- #5004-A gene expression profile of BRCAness that correlates with responsiveness to platinum and PARP inhibitors.

Panagiotis Konstantinopoulos

- #5005-Randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): A NOGGO-AGO-Intergroup study.

Jalid Sehouli, Prof., Dr.

- #5006-RTOG 0417: A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma.

Tracey E Schefter

- Discussion: The next Step in Chemo-radiation for cervical cancer.

Patricia J. Eifel, MD

- 5 #5013-Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer.

Ignace B. Vergote

- Discussion: Chemotherapy of the future in platinum resistant disease.

Claire F. Verschraegen, MD

- #LBA5008-Phase III trial of induction gemcitabine (G) or paclitaxel (T) plus carboplatin (C) followed by elective T consolidation in advanced ovarian cancer (OC): Final safety and efficacy report.

Michael G. Teneriello

- Discussion: Maintenance and Consolidation in Ovarian Cancer.

Ronald J. Buckanovich, MD

Session Title: #143: Plenary Session including Science of Oncology Award and Lecture

Session Type: Plenary Session

Date: Sunday, June 6

Location: N Hall B1

Time: 1:00 PM - 4:00 PM

- Plenary Session including Science of Oncology Award and Lecture

Douglas W. Blayney, MD

- Plenary Session including Science of Oncology Award and Lecture

Daniel F. Hayes, MD

- Plenary Session including Science of Oncology Award and Lecture

Frank McCormick, PhD, FRS

- #LBA1-Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

Robert A Burger

- Discussion

Elizabeth A. Eisenhauer, MD

- #2-Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).

Elisabeth A. Quoix

- #3-Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive patients with non-small cell lung cancer (NSCLC).

Yung-Jue Bang

- Discussion

Martin J. Edelman, MD

- #4-A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

Steven O'Day, MD

- Discussion: Ipilimumab: The light at the end of the tunnel?

Vernon K Sondak, MD

Session Title: #181: Gynecologic Cancer

Session Type: Poster Discussion Session

Date: Sunday, June 6

Location: E450a

Time: 2:00 PM - 6:00 PM

- Gynecologic Cancer

Seiko Diane Yamada, MD

- Gynecologic Cancer

Claire F. Verschraegen, MD

1 #5009-A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.

Todd D. Tillmanns

2 #5010-A phase II evaluation of nab-paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group (GOG) study.

Robert L. Coleman, MD

3 #5011-A phase II, nonrandomized study of nab-paclitaxel plus carboplatin in patients with recurrent platinum-sensitive ovarian or primary peritoneal cancer.

Benedict B. Benigno

4 #5012-Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone: Results from a PPS cohort of a phase III study.

Andres Poveda

5 #LBA5012b-PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.

R. Wendel Naumann

6 #5014-Phase II study of danusertib (D) in advanced/metastatic breast and ovarian cancers (BC, OC).

Elisa Gallerani

7 #5015-Immunotherapy with intraperitoneal catumaxomab in patients with advanced ovarian cancer after a complete response to chemotherapy: A phase II study.

Robert W. Holloway

- Discussion: old wines in new bottles.

Carol Aghajanian, MD

8 #5016-A KRAS-variant as a biomarker of ovarian cancer risk.

Joanne B. Weidhaas

9 #5017-Clinical characteristics and outcomes of BRCA-associated ovarian cancer (OC): Genotype and survival.

Verena Engelstaedter

10 #5018-Breast cancer protein expression as a prognostic marker in sporadic epithelial ovarian cancer (EOC): An NCIC CTG OV.16 correlative study.

Johanne Ingrid Weberpals

11 #5019-Impact of BRCA1 gene alterations on tumor characteristics and clinical outcome in ovarian cancer (OC) patients.

Desislava Dimitrova

12 #5020-Use of microarray-based comparative genomic hybridization analysis to identify prognostic subgroups of ovarian clear cell carcinomas.

David Shao Peng Tan

13 #5021-A gene expression algorithm for the prediction of platinum sensitivity in ovarian cancer.

James Stuart Ferriss, MD

14 #5022-Use of HE4 expression in plasma to predict operative outcome in patients with ovarian cancer (OC).

Elena Ioana Braicu

- Discussion: Biomarkers in ovarian cancer - forward progress or back to the future?

Michael J. Birrer, MD, PhD

16 #5024-Performance of PREMM1,2,6, MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases.

Rowena Cabigon Mercado

17 #5025-Impact of microsatellite instability in overall survival of women with endometrial cancer.

Jose Claudio Casali da Rocha, MD, PhD

18 #5026-Evaluation of insulin resistance among endometrial cancer patients.

Jennifer K. Burzawa

19 #5027-Influence of radiation modality and nodal dissection on survival in high-risk early-stage endometrial cancer.

Junzo P. Chino

20 #5028-Adjuvant chemotherapy and chemoradiation following surgery for high-risk endometrial cancer.

Kailash Narayan

21 #5029-A phase II trial of radiotherapy sandwiched between carboplatin and docetaxel for stage III, IV, and recurrent endometrial cancer.

Melissa Ann Geller, MD

- Discussion: Whats new in Endometrial Cancer?

Angeles Alvarez Secord, MD

22 #5030-Treatment outcomes for older women with advanced ovarian cancer: Results from a phase III clinical trial (GOG182).

William P. Tew

23 #5031-Can elderly patients with recurrent ovarian cancer (ROC) be treated with a platinum-based doublet? Results from the CALYPSO trial.

Jean-Emmanuel Kurtz

24 #5032-Defining clinical and statistical improvement in consolidation single-arm trials in ovarian cancer.

David R. Spriggs, MD

25 #LBA5033-Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO-2 randomized multicenter trial.

Sandro Pignata

- Discussion: Mining Phase III studies - gold or quicksilver?

Mahesh Parmar, PhD

Session Title: #248: Gynecologic Cancer

Session Type: Poster Discussion Session

Date: Sunday, June 6

Location: E Arie Crown Theater

Time: 5:00 PM - 6:00 PM

- Gynecologic Cancer

Seiko Diane Yamada, MD

- Gynecologic Cancer

Claire F. Verschraegen, MD

1 #5009-A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.

Todd D. Tillmanns

2 #5010-A phase II evaluation of nab-paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group (GOG) study.

Robert L. Coleman, MD

3 #5011-A phase II, nonrandomized study of nab-paclitaxel plus carboplatin in patients with recurrent platinum-sensitive ovarian or primary peritoneal cancer.

Benedict B. Benigno

4 #5012-Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone: Results from a PPS cohort of a phase III study.

Andres Poveda

5 #LBA5012b-PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.

R. Wendel Naumann

6 #5014-Phase II study of danusertib (D) in advanced/metastatic breast and ovarian cancers (BC, OC).

Elisa Gallerani

7 #5015-Immunotherapy with intraperitoneal catumaxomab in patients with advanced ovarian cancer after a complete response to chemotherapy: A phase II study.

Robert W. Holloway

- Discussion: old wines in new bottles.

Carol Aghajanian, MD

8 #5016-A KRAS-variant as a biomarker of ovarian cancer risk.

Joanne B. Weidhaas

9 #5017-Clinical characteristics and outcomes of BRCA-associated ovarian cancer (OC): Genotype and survival.

Verena Engelstaedter

10 #5018-Breast cancer protein expression as a prognostic marker in sporadic epithelial ovarian cancer (EOC): An NCIC CTG OV.16 correlative study.

Johanne Ingrid Weberpals

11 #5019-Impact of BRCA1 gene alterations on tumor characteristics and clinical outcome in ovarian cancer (OC) patients.

Desislava Dimitrova

12 #5020-Use of microarray-based comparative genomic hybridization analysis to identify prognostic subgroups of ovarian clear cell carcinomas.

David Shao Peng Tan

13 #5021-A gene expression algorithm for the prediction of platinum sensitivity in ovarian cancer.

James Stuart Ferriss, MD

14 #5022-Use of HE4 expression in plasma to predict operative outcome in patients with ovarian cancer (OC).

Elena Ioana Braicu

- Discussion: Biomarkers in ovarian cancer - forward progress or back to the future?

Michael J. Birrer, MD, PhD

16 #5024-Performance of PREMM1,2,6, MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases.

Rowena Cabigon Mercado

17 #5025-Impact of microsatellite instability in overall survival of women with endometrial cancer.

Jose Claudio Casali da Rocha, MD, PhD

18 #5026-Evaluation of insulin resistance among endometrial cancer patients.

Jennifer K. Burzawa

19 #5027-Influence of radiation modality and nodal dissection on survival in high-risk early-stage endometrial cancer.

Junzo P. Chino

20 #5028-Adjuvant chemotherapy and chemoradiation following surgery for high-risk endometrial cancer.

Kailash Narayan

21 #5029-A phase II trial of radiotherapy sandwiched between carboplatin and docetaxel for stage III, IV, and recurrent endometrial cancer.

Melissa Ann Geller, MD

- Discussion: Whats new in Endometrial Cancer?

Angeles Alvarez Secord, MD

22 #5030-Treatment outcomes for older women with advanced ovarian cancer: Results from a phase III clinical trial (GOG182).

William P. Tew

23 #5031-Can elderly patients with recurrent ovarian cancer (ROC) be treated with a platinum-based doublet? Results from the CALYPSO trial.

Jean-Emmanuel Kurtz

24 #5032-Defining clinical and statistical improvement in consolidation single-arm trials in ovarian cancer.

David R. Spriggs, MD

25 #LBA5033-Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO-2 randomized multicenter trial.

Sandro Pignata

- Discussion: Mining Phase III studies - gold or quicksilver?

Mahesh Parmar, PhD

Session Title: #168: Highlights of the Day II including Partners in Progress Award

Session Type: Highlights of the Day

Date: Monday, June 7

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day II including Partners in Progress Award

Douglas W. Blayney, MD

- Highlights of the Day II including Partners in Progress Award

Kim Allyson Margolin, MD

- Partners in Progress Award Recipient

Ellen V. Sigal, PhD

- Discussion: Genitourinary (Prostate) Cancer

Nicholas J. Vogelzang, MD

- Discussion: Gastrointestinal (Colorectal) Cancer

Howard S. Hochster, MD

- Discussion: Gynecologic Cancer

Claire F. Verschraegen, MD

- Discussion: Myeloma

Jean L. Harousseau, MD

- Discussion: Cancer Prevention/Epidemiology

Scott Michael Lippman, MD

Session Title: #224: Novel Therapies and Approaches for Management of Gynecologic Cancers

Session Type: Clinical Science Symposium

Date: Monday, June 7

Location: E Arie Crown Theater

Time: 9:45 AM - 11:15 AM

- Novel Therapies and Approaches for Management of Gynecologic Cancers

Robert L. Coleman, MD

- Novel Therapies and Approaches for Management of Gynecologic Cancers

Ronald J. Buckanovich, MD

- #5000-Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma.

Beth Y. Karlan

- Discussion: Anti-angiogenic options in Ovarian Cancer. (Please take note of other PK abstract with AMG 386. Abst 47850)

George Coukos, MD, PhD

- #5001-Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study.

Allan J. White, MD

- Discussion: Targeting the folate receptor in ovarian cancer. (Please also note functional folate receptor imaging abstract 44469)

Alan Hilary Calvert, MD

- #5002-Final results of a phase II study of voreloxin in women with platinum-resistant ovarian cancer.

Hal W. Hirte

- Discussion: Mechanisms of resistance in ovarian cancer.

Hani Gabra, PhD, FRCP

Session Title: #63: Integrated Considerations in the Management of the Patient with Advanced Ovarian Cancer

Session Type: Education Session

Date: Monday, June 7

Location: E Arie Crown Theater

Time: 3:00 PM - 4:15 PM

- Balancing Biologic Behavior with Surgical Therapy

Andreas Du Bois, MD, PhD

- The Promise and Toxicity of Novel Targeted Therapies in Ovarian Cancer: Hope or Hype?

Elise C. Kohn, MD

- Does Palliative Chemotherapy Palliate? Assessment of Symptom Benefit in Recurrent Ovarian Cancer

Michael Friedlander, MD, PhD

Session Title: #169: Highlights of the Day III

Session Type: Highlights of the Day

Date: Tuesday, June 8

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day III

Kathy Miller, MD

- Discussion: Breast Cancer - Local/Regional and Adjuvant Therapy

Kathy Miller, MD

- Discussion: Lung Cancer - Metastatic

Charles M. Rudin, MD, PhD

- Discussion: Sarcoma

Gary K. Schwartz, MD

- Discussion: Gastrointestinal (Noncolorectal) Cancer

C. D. Blanke, MD

- Discussion: Head and Neck Cancer

Everett E. Vokes, MD